Clinical responses
| Patient* . | Response to cytoreductive chemotherapy . | Response to T-cell Infusions† . | Duration of response after T-cell infusions, mo‡ . |
|---|---|---|---|
| A | CR | NED | 13 |
| B | PR | SD | 3 |
| D | SD | SD | 12 |
| F | CR | NED | 3 |
| G | Did not receive chemotherapy | SD (with FDG response on PET scan) | 5 |
| H | PR | PR§ | 3 |
| I | PR | SD | 6 |
| Patient* . | Response to cytoreductive chemotherapy . | Response to T-cell Infusions† . | Duration of response after T-cell infusions, mo‡ . |
|---|---|---|---|
| A | CR | NED | 13 |
| B | PR | SD | 3 |
| D | SD | SD | 12 |
| F | CR | NED | 3 |
| G | Did not receive chemotherapy | SD (with FDG response on PET scan) | 5 |
| H | PR | PR§ | 3 |
| I | PR | SD | 6 |
CR indicates complete response; NED, no evidence of disease; PR, partial response; SD, stable disease; FDG, fluorodeoxyglucose; and PET, positron emission tomography.
Patients C and E are omitted because they did not receive T-cell infusions.
Response assessment was performed compared with the restaging imaging after cytoreductive chemotherapy.
All patients progressed after the times listed.
Patient H achieved an additional objective PR after T-cell infusions.